Compare Amgen, Inc. (AMGN) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Uber Technologies Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Uber Technologies Inc trades at $75.11 (market cap $151.73B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays a 2.77% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| AMGN | UBER | |
|---|---|---|
Market Cap | $196.12B | $151.73B |
Sector | Health | Industrials |
52-Week High | $388.16 | $100.10 |
52-Week Low | $271.18 | $68.61 |
Enterprise Value | $241.41B | $158.06B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Uber Technologies (UBER) trades at $74.54, showing modest daily gains of 0.26%. The stock maintains strong bullish technical momentum with positive moving average signals and trades near pivot point resistance at $75. Fundamentally, Uber demonstrates robust revenue growth from $31.9B in 2022 to $52.0B in 2025, with net income turning positive since 2023 and reaching $10.05B in 2025. Recent developments include strategic moves into autonomous vehicles with robotaxi pilots in Madrid and Munich.
Uber presents a compelling growth story with expanding profitability and dominant market position. The 81.7% analyst buy rating and $109.25 consensus price target suggest 46% upside potential. Key risks include execution challenges in autonomous vehicle expansion, competitive pressures in key markets like India, and potential margin compression as revenue growth moderates. The negative projected net cash flow for 2026 warrants monitoring of capital allocation strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
